Abrocitinib Oral Suspension(Pfizer)
阿布昔替尼口服混悬液（辉瑞）
Report date: 2026/04/08 15:33:15
Base Information
Drug NameAbrocitinib Oral Suspension(Pfizer)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A